Trial Profile
Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Chronic heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms PRESERVED-HF
- 13 Nov 2023 Results of Patient-level data were pooled from the DEFINE-HF and PRESERVED-HF presented, at the American Heart Association Scientific Sessions 2023
- 01 Jul 2023 Results of pooled analysis of DEFINE-HF & PRESERVED-HF assessing effect of dapagliflozin on the change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at 12 weeks was tested with ANCOVA adjusted for sex, baseline KCCQ, EF, atrial fibrillation, estimated glomerular filtration rate, and type 2 diabetes, published in the Circulation: Heart Failure.
- 21 Dec 2021 Status changed from active, no longer recruiting to completed.